Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Coriolis Pharma | Contract Pharma

What are you searching for?

Sign in

Search by

Coriolis Pharma

Coriolis Pharma

Company Headquarters

18B Fraunhoferstrasse, Planegg, 82152, DE

Driving Directions Phone: View Phone Fax: View Fax
View website

Company Description

Coriolis Pharma is a global contract research and development organization (CRDO) and the premier partner for the development of liquid and lyophilized drug products, analytical services, and manufacturing services across a vast array of therapeutic modalities, including biologics, gene and cell therapies and vaccines. Our scientists design and execute platform and custom services to accelerate and de-risk your program right from the start and throughout the entire product lifecycle.

Request more information from Coriolis Pharma

Request more information from Coriolis Pharma

Categories from Coriolis Pharma

Accelerated Stability Studies
Agglomeration
Analytical Laboratory Services
Analytical Methods Development
Analytical Validation Studies
Bioanalytical Analysis LC/MS/MS
Bioanalytical Services
Biological Testing
Biosimilars
Chemical Analysis
Chromatographic Analysis, LC/GC
Chromatography
Container Testing
Contract Manufacturing
Contract Research
Custom Manufacturing
Dosage Form Development
Drug Development Services
Excipients
Feasibility Studies
Filling, Cartridge
Filling, Syringe
Filling, Vial
Forced Degradation Studies
Formulation Development
Formulation Services
Formulation, Controlled Release
Gene Therapy & Testing Protocols
High Throughput Screening
HPLC
In Vitro Testing
Lot Release Testing
Lyophilization
Manufacturing, Aseptic Fill/Finish
Manufacturing, Liquids
Manufacturing, Lyophilized Products
Mass Spectrometry
Methods Development
Methods Validation
Micro FT-IR Analysis
Microscopic Analysis
Nonclinical Research
Parenterals Development
Parenterals, Cartridge Filling
Parenterals, Syringe Filling
Parenterals, Vial Filling
Particle Characterization
Particle Size Analysis
Particle Size Classification
Photostability
Physical Testing
Pilot-Scale Filling
Polymerase Chain Reaction
Preclinical Study Design
Preclinical Testing Formulations
Preformulation
Process Analytical Technology (PAT)
Process Characterization
Process Development/Scale-Up Services
Process R&D
Process Validation Studies
Project Management
Protein Extraction/Purification
Purification
QA/QC
Quality Control Testing
R&D Services
Scale-Up
Stability Studies
Stability, ICH
Syringe Filling
UV-VIS Spectrophotometer Analysis
X-Ray Powder Diffraction

Related Content

Breaking News

Asahi Kasei Launches VANTIJ SU-VFC Benchtop

New platform streamlines small-scale virus filtration for biopharma and gene therapy workflows.

By: Charlie Sternberg

Collaborations & Alliances

Exegenesis Bio, Modalis Partner on DMD Gene Therapy

The collaboration pairs Exegenesis Bio’s EMC181 muscle-tropic AAV capsid with Modalis’ CRISPR-GNDM platform to advance MDL-201.

By: Charlie Sternberg

Collaborations & Alliances

Genprex Selects Andelyn Biosciences to Scale Manufacturing for Diabetes Gene Therapy Program

Andelyn will use its Curator cell and gene therapy platform to transition Genprex’s candidate in support of clinical trials.

By: Patrick Lavery

Collaborations & Alliances

Biohaven, SK Biopharmaceuticals Ink Licensing Pact for Next-Gen Epilepsy Candidate

The companies will collaborate to advance the treatment through development and FDA approval.

By: Patrick Lavery

Breaking News

Cytovance Biologics Expands Analytical Services Portfolio with Standalone Capabilities

Customers can engage Cytovance for analytical method development, transfer, qualification, validation, product characterization, release testing, stability studies, and storage.

By: Patrick Lavery

Collaborations & Alliances

Andelyn Biosciences Partners With Queen’s University on GM2 Gene Therapy

CDMO to manufacture AAV9-GM2 candidate for Tay-Sachs and Sandhoff diseases.

By: Charlie Sternberg

Breaking News

PTC to Acquire Sangamo’s Fabry Disease Gene Therapy

ST-920 is a one-time administered AAV gene therapy undergoing BLA review for Fabry disease.

By: Charlie Sternberg

Features

The CDMO Capacity Crunch Persists

Nearly half of biopharma companies report difficulty finding mammalian production capacity, while cell and gene therapy face even tighter constraints.

By: Katrina Cordovado

Optimizing Plasmid Manufacturing for Cell and Gene Therapy

Sponsored By ProBio CDMO

Collaborations & Alliances

Circio, Avenue Biosciences Partner on Gene Therapy Protein Expression

Collaboration combines Circio’s circVec platform with Avenue’s protein engineering technology to improve secretion of therapeutic proteins.

By: Charlie Sternberg

Collaborations & Alliances

Catalent, Nanoscope Expand MCO-010 Gene Therapy Partnership

Catalent will support commercial packaging and distribution as Nanoscope advances its rolling BLA submission.

By: Charlie Sternberg

Features

Cell & Gene Therapy CDMO Partnerships

Alliances and expertise behind advancing CGTs in today’s market.

By: Kristin Brooks

Collaborations & Alliances

Circio, GenAssist Partner on AAV Gene Therapy

Collaboration targets lower-dose therapies for genetic muscle disease and in vivo cell therapy.

By: Charlie Sternberg

Online Exclusives

Single-Use Becomes the CGT Baseline

Margin compression, tariff exposure, and supplier consolidation are piling pressure on contract manufacturers. But single-use technology redrew the competitive landscape and a second wave in cell and gene therapy is doing it again.

By: Dan Stanton

Collaborations & Alliances

Circio, AaviGen Launch Heart Gene Therapy Collaboration

Biotech companies partner to develop low-dose, targeted AAV gene therapies for cardiac disease.

By: Charlie Sternberg